Corcoran Ryan B, Bachar Raveh Tal, Barakat Monique T, Lee Eunice Y, Scott Matthew P
Department of Developmental Biology, Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, California 94305, USA.
Cancer Res. 2008 Nov 1;68(21):8788-95. doi: 10.1158/0008-5472.CAN-08-2135.
Medulloblastoma (MB) can arise in the cerebellum due to genetic activation of the Sonic Hedgehog (Shh) signaling pathway. During normal cerebellum development, Shh spurs the proliferation of granule neuron precursors (GNP), the precursor cells of MB. Mutations in the Shh receptor gene patched1 (ptc1+/-) lead to increased MB incidence in humans and mice. MB tumorigenesis in mice heterozygous for ptc1+/- shows distinct steps of progression. Most ptc1+/- mice form clusters of preneoplastic cells on the surface of the mature cerebellum that actively transcribe Shh target genes. In approximately 15% of mice, these preneoplastic cells will become fast-growing, lethal tumors. It was previously shown that the loss of function of insulin-like growth factor 2 (igf2) suppresses MB formation in ptc1+/- mice. We found that igf2 is not expressed in preneoplastic lesions but is induced as these lesions progress to more advanced MB tumors. Igf2 is not required for formation of preneoplastic lesions but is necessary for progression to advanced tumors. Exogenous Igf2 protein promoted proliferation of MB precursor cells (GNP) and a MB cell line, PZp53(MED). Blocking igf2 signaling inhibited growth of PZp53(MED) cells, implicating igf2 as a potential clinical target.
髓母细胞瘤(MB)可因 Sonic Hedgehog(Shh)信号通路的基因激活而在小脑发生。在正常小脑发育过程中,Shh 刺激颗粒神经元前体细胞(GNP)增殖,而 GNP 是 MB 的前体细胞。Shh 受体基因 patched1(ptc1+/-)的突变会导致人类和小鼠中 MB 发病率增加。ptc1+/-杂合小鼠中的 MB 肿瘤发生呈现出不同的进展阶段。大多数 ptc1+/-小鼠在成熟小脑表面形成前肿瘤细胞簇,这些细胞会积极转录 Shh 靶基因。在大约 15%的小鼠中,这些前肿瘤细胞会发展成为快速生长的致命肿瘤。先前的研究表明,胰岛素样生长因子 2(igf2)功能丧失可抑制 ptc1+/-小鼠中的 MB 形成。我们发现,igf2 在肿瘤前病变中不表达,但随着这些病变发展为更晚期的 MB 肿瘤而被诱导表达。igf2 对于肿瘤前病变的形成不是必需的,但对于进展为晚期肿瘤是必需的。外源性 Igf2 蛋白促进了 MB 前体细胞(GNP)和一种 MB 细胞系 PZp53(MED)的增殖。阻断 igf2 信号传导抑制了 PZp53(MED)细胞的生长,这表明 igf2 是一个潜在的临床靶点。